Stock Events

Stock Events

Big Rock partners Acquisition 

€0.000000
105
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q1 2026
Next
-0.1
-0.01
0.09
0.18
Expected EPS
-0.0987065095
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B1Q.STU. It's not an investment recommendation.
Tesla
17
TSLA
NVIDIA
14
NVDA
Apple
13
AAPL
Microsoft
12
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap138.61B
Pfizer is a global pharmaceutical company that competes with NRX Pharmaceuticals in the development and marketing of medications for various therapeutic areas, including mental health.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in developing treatments for disorders that NRX Pharmaceuticals targets, including mental health and other areas.
Merck
MRK
Mkt Cap319.99B
Merck & Co. is involved in the research, development, and marketing of drugs that address conditions similar to those targeted by NRX Pharmaceuticals, making them a direct competitor.
Lilly(Eli) &
LLY
Mkt Cap1.08T
Eli Lilly and Company competes with NRX Pharmaceuticals in the psychiatric and neurological drug market, particularly in areas like depression and bipolar disorder.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie competes in the neuroscience and mental health drug market, areas that are of interest to NRX Pharmaceuticals, with a strong portfolio in psychiatric drugs.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb offers a range of products that compete in the therapeutic areas targeted by NRX Pharmaceuticals, including mental health treatments.
Novartis
NVS
Mkt Cap305.1B
Novartis AG competes with NRX Pharmaceuticals through its extensive research and development in therapies for neurological and mental health conditions.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline competes in the pharmaceutical market for mental health medications, a key area of focus for NRX Pharmaceuticals.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical Industries is a global competitor in generic and specialty medicines, including those for neurological and psychiatric conditions that NRX Pharmaceuticals also targets.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca is involved in the development of therapies for various diseases, including those in the neurological and psychiatric domain, making them a competitor to NRX Pharmaceuticals.

About

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Show more...
CEO
Dr. Jonathan C. Javitt M.D., M.P.H.
Employees
2
Country
United States
ISIN
US0894821034

Listings

MU
DE
B1Q.MU
XNAS
US
NRXP
STU
DE
B1Q.STU
F
DE
B1Q.F

0 Comments

Share your thoughts

FAQ

What is Big Rock partners Acquisition stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Big Rock partners Acquisition stocks are traded under the ticker B1Q.STU.
When is the next Big Rock partners Acquisition earnings date?▼
Big Rock partners Acquisition is going to release the next earnings report on August 17, 2026.
What were Big Rock partners Acquisition earnings last quarter?▼
B1Q.STU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was 0.18 EUR resulting in a -119.14% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Big Rock partners Acquisition have?▼
As of July 10, 2026, the company has 2 employees.
In which sector is Big Rock partners Acquisition located?▼
Big Rock partners Acquisition operates in the Health & Wellness sector.
When did Big Rock partners Acquisition complete a stock split?▼
Big Rock partners Acquisition has not had any recent stock splits.
Where is Big Rock partners Acquisition headquartered?▼
Big Rock partners Acquisition is headquartered in Wilmington, United States.